Cases & Deals

  • Home
  • Practices
  • Reneo Pharmaceuticals announces reverse merger with OnKure

Share

Reneo Pharmaceuticals announces reverse merger with OnKure

May 2024

Client(s) Reneo Pharmaceuticals, Inc.

Jones Day is representing Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) in an all-stock reverse merger between Reneo and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company valued at $170 million that is focused on the development of novel precision medicines in oncology. Upon completion of the transaction, the combined company will be traded on the Nasdaq Global Market and will focus on advancing OnKure's portfolio of novel precision oncology medicines targeting oncogenic mutations in PIK3a.

The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.